Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to tackle tough lymphoma

NCT ID NCT06929624

Disease control Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This phase 3 trial tests whether adding the experimental drug SHR-A1912 to standard chemotherapy (R-GEMOX) helps people with relapsed or refractory diffuse large B-cell lymphoma. About 280 adults whose cancer came back after at least one prior treatment will be randomly assigned to receive either the new combo or standard chemo alone. The main goals are to see if more patients achieve complete remission and if overall survival improves.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SHR-A1912 (a targeted drug) combined with rituximab, gemcitabine, and oxaliplatin (chemotherapy)
What this could lead to
If successful, this combination could offer a new treatment option for people with relapsed or refractory diffuse large B-cell lymphoma, potentially improving response rates and survival.
What could go wrong
This is an early-phase 3 trial, so results are not yet known. The added drug may increase side effects, and the benefit over standard therapy is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 280 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Histologically confirmed diffuse large B-cell lymphoma (DLBCL). 2. Have received ≥1 line of systemic antitumor therapy. 3. At least one bi-dimensionally measurable lesion. 4. Expected survival of at least 3 months. 5. Age ≥18 years old and under 80 years old. 6. The patients voluntarily participated in the study, signed informed consent, had good compliance and were willing to cooperate with follow-up. Exclusion Criteria: 1. Central nervous system lymphoma involvement. 2. Primary mediastinal (thymus) large B-cell lymphoma. 3. Patients who have only one prior line therapy and are candidates for stem cell transplantation. 4. A history of immunodeficiency. 5. A history of severe cardiovascular disease. 6. A history of other malignancies within 5 years prior to administration of the first dose.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diffuse large B-cell lymphoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diffuse large B-cell lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Cancer Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100142, China

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.